MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
CoTec Holdings Corp. Joint Venture, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub
Excalibur Intersects 360 g/t Silver & 2 g/t Gold over 1.52m at Bellehelen; 100m Broad Mineralized Zone Remains Open at Depth
